Morphic Holding Analyst Ratings
RBC Capital Maintains Morphic(MORF.US) With Hold Rating, Maintains Target Price $57
Analysts Have Conflicting Sentiments on These Healthcare Companies: Morphic Holding (MORF), Pyxis Oncology (PYXS) and Zynex (ZYXI)
Morphic Holding (MORF) Receives a Hold From RBC Capital
Analysts' Opinions Are Mixed on These Healthcare Stocks: HCA Healthcare (HCA), Oric Pharmaceuticals (ORIC) and GoodRx Holdings (GDRX)
Morphic Holding Analyst Ratings
AnaptysBio Price Target Announced at $55.00/Share by HC Wainwright & Co.
Stifel Nicolaus Keeps Their Hold Rating on Morphic Holding (MORF)
AnaptysBio's Promising Pipeline and Rosnilimab's Best-in-Class Potential Justify Buy Rating
AnaptysBio Analyst Ratings
JPMorgan Upgrades AnaptysBio to Overweight From Neutral, Adjusts Price Target to $69 From $29
Praxis Precision Medicines (PRAX) Gets a Buy From Piper Sandler
Leerink Partners Sticks to Its Buy Rating for AnaptysBio (ANAB)
Analysts Are Bullish on Top Healthcare Stocks: Oric Pharmaceuticals (ORIC), Ufp Technologies (UFPT)
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Applied Therapeutics (APLT) and Oric Pharmaceuticals (ORIC)
ORIC Pharmaceuticals Analyst Ratings
UniQure Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on UniQure, Maintains $24 Price Target
Jefferies Downgrades Morphic Holding to Hold From Buy, Price Target Is $57
Longboard Pharmaceuticals Analyst Ratings